NCT05976763 2026-03-04
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06742996 2026-02-20
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
Phase 3 Recruiting
NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06558604 2026-02-11
GLOASIS
The Lymphoma Academic Research Organisation
Phase 2 Recruiting
NCT06839053 2025-11-19
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT06029309 2025-10-06
ZANU-TAFA
University of Miami
Phase 1/2 Recruiting
NCT06859008 2025-08-05
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT05635162 2025-04-16
ZEBRA
University College, London
Phase 2 Recruiting
NCT06341556 2024-09-04
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Fudan University
Phase 2 Recruiting
NCT06504199 2024-08-09
ZGR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06136351 2023-11-29
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Recruiting